schliessen

Filtern

 

Bibliotheken

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies. Effects on... Full description

Journal Title: American Heart Journal 2013, Vol.166 (2), p.217-223.e11
Main Author: Neal, Bruce, PhD
Other Authors: Perkovic, Vlado, PhD , de Zeeuw, Dick, PhD , Mahaffey, Kenneth W., MD , Fulcher, Greg, MD , Stein, Peter, MD , Desai, Mehul, MD , Shaw, Wayne, DSL , Jiang, Joel, PhD , Vercruysse, Frank, MD , Meininger, Gary, MD , Matthews, David, DPhil
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: United States: Mosby, Inc
ID: ISSN: 0002-8703
Link: https://www.ncbi.nlm.nih.gov/pubmed/23895803
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1416045751
title: Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
format: Article
creator:
  • Neal, Bruce, PhD
  • Perkovic, Vlado, PhD
  • de Zeeuw, Dick, PhD
  • Mahaffey, Kenneth W., MD
  • Fulcher, Greg, MD
  • Stein, Peter, MD
  • Desai, Mehul, MD
  • Shaw, Wayne, DSL
  • Jiang, Joel, PhD
  • Vercruysse, Frank, MD
  • Meininger, Gary, MD
  • Matthews, David, DPhil
subjects:
  • Abridged Index Medicus
  • Aged
  • Biomarkers - blood
  • Blood sugar
  • Body mass index
  • Canagliflozin
  • Cardiology
  • Cardiovascular
  • Cardiovascular disease
  • Cardiovascular Diseases - mortality
  • Cardiovascular Medicine
  • Clinical trials
  • Diabetes
  • Diabetes Mellitus, Type 2 - drug therapy
  • Double-Blind Method
  • Drug therapy
  • Electrocardiography
  • Female
  • GLUCOSE
  • Glucose metabolism
  • Glucosides - adverse effects
  • Glucosides - therapeutic use
  • Health aspects
  • Heart failure
  • Hemoglobin
  • Humans
  • Hypertension
  • Hypoglycemic Agents - adverse effects
  • Hypoglycemic Agents - therapeutic use
  • Male
  • Middle Aged
  • Plasma
  • Regulatory approval
  • Research Design
  • Sodium-Glucose Transporter 2 - antagonists & inhibitors
  • Statins
  • Thiophenes - adverse effects
  • Thiophenes - therapeutic use
  • Triglycerides
  • TUBULAR REABSORPTION
  • Type 2 diabetes
ispartof: American Heart Journal, 2013, Vol.166 (2), p.217-223.e11
description: Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies. Effects on macrovascular complications of diabetes remain to be determined. CANVAS is a double-blind, placebo-controlled trial designed to evaluate the effects of canagliflozin on the risk of cardiovascular disease and to assess safety and tolerability in patients with inadequately controlled T2DM and increased cardiovascular risk. The first of 2 planned phases randomized 4,330 individuals to placebo, canagliflozin 100 or 300 mg (1:1:1) with planned follow-up of about 2 years to substantiate potential cardiovascular protection by assessing key biomarkers and to achieve initial safety objectives. By the end of mid-September 2012, a total of 7174 patient-years of follow-up were accrued. Mean baseline age was 62 years, duration of diabetes 13 years; hemoglobin A1c 8.2%, fasting plasma glucose 9.3 mmol/L, and body mass index 32 kg/m2 . Of the participants, 34% are female and 57% had a history of atherosclerotic vascular disease. Participants will be followed up to achieve primary safety and tolerability objectives and to investigate secondary outcomes. The planned second phase will not be undertaken. CANVAS will define the effects of canagliflozin on biomarkers and provide data on cardiovascular safety against established regulatory parameters.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7624338
LOCALfalse
PrimoNMBib
record
control
sourceidgale_opena
recordidTN_cdi_proquest_miscellaneous_1416045751
sourceformatXML
sourcesystemPC
galeidA338804319
sourcerecordidA338804319
originalsourceidFETCH-LOGICAL-1705t-c0edb8c5014e19b970ce57a2fa9535af7caaf66a175172a1ed8d7d7c6d6927113
addsrcrecordideNp9U9tu1DAQjRCIlsIH8IIi8VKk7jLOzYmQkFYrblJVJBZ44cFy7MnWi9de7KSofeIj4Af5Eibd0ooVqvKQjHXOmXHOmSR5zGDKgFXPV1N5uppmwPIplFMAfifZZ9DwScWL4m6yDwDZpOaQ7yUPYlxRWWV1dT_Zy_K6KWvI95NfH2RvvJMWj1KN0SzdUSqdTlsZ0RqHqTqVQaoeg4m9UTH1XdqfYjqXTi6t6ay_MI6qoI0_k1ENVoZ0FiPGuEbXp4t-0Ofp4Xx28nm2ePb7x89ZGkjfr80F6nRjpcLWT5R3ffDW0lEfjLQPk3udtBEfXb0Pkk-vX32cv50cv3_zbj47njAOZT9RgLqtVQmsQNa0DQeFJZdZJ5syL2XHlZRdVUnGS8YzyVDXmmuuKl01GWcsP0hOtrp-g06agGITzFqGc-GlEdphLzTqYSO-dwKAiaoGaJAaUf9clqxoMmioW5HndV0XGQkebgU3wX8bMPZibaJCa6VDP0TBClZBUdI8BH26A135IZAThCrLImuqvKhvUEuySBjX-Z7sGEXFbGwKRc4aQk3_g6JH49rQz8XO0Pk_BLYlqOBjDNhdX5yBGLMlVoKyJcZsCSjp8pw4T64GHto16mvG3zARgO-IKtNfxoumMfZW6S9bppNBmXgtHYblpRObgawZC2fpu7VGXcpGoVRZaca1yNtWiSLLGtEidKKCusCOccRuNOXFVh0pSmcGg4jKoFOoyXFFFntz62wvd9iKFoMmsF_xHOONaSJmAsRiXLpx51gOQA7y_A-7lyWc
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1554296348
display
typearticle
titleRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
sourceAlma/SFX Local Collection
creatorNeal, Bruce, PhD ; Perkovic, Vlado, PhD ; de Zeeuw, Dick, PhD ; Mahaffey, Kenneth W., MD ; Fulcher, Greg, MD ; Stein, Peter, MD ; Desai, Mehul, MD ; Shaw, Wayne, DSL ; Jiang, Joel, PhD ; Vercruysse, Frank, MD ; Meininger, Gary, MD ; Matthews, David, DPhil
creatorcontribNeal, Bruce, PhD ; Perkovic, Vlado, PhD ; de Zeeuw, Dick, PhD ; Mahaffey, Kenneth W., MD ; Fulcher, Greg, MD ; Stein, Peter, MD ; Desai, Mehul, MD ; Shaw, Wayne, DSL ; Jiang, Joel, PhD ; Vercruysse, Frank, MD ; Meininger, Gary, MD ; Matthews, David, DPhil
descriptionSodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies. Effects on macrovascular complications of diabetes remain to be determined. CANVAS is a double-blind, placebo-controlled trial designed to evaluate the effects of canagliflozin on the risk of cardiovascular disease and to assess safety and tolerability in patients with inadequately controlled T2DM and increased cardiovascular risk. The first of 2 planned phases randomized 4,330 individuals to placebo, canagliflozin 100 or 300 mg (1:1:1) with planned follow-up of about 2 years to substantiate potential cardiovascular protection by assessing key biomarkers and to achieve initial safety objectives. By the end of mid-September 2012, a total of 7174 patient-years of follow-up were accrued. Mean baseline age was 62 years, duration of diabetes 13 years; hemoglobin A1c 8.2%, fasting plasma glucose 9.3 mmol/L, and body mass index 32 kg/m2 . Of the participants, 34% are female and 57% had a history of atherosclerotic vascular disease. Participants will be followed up to achieve primary safety and tolerability objectives and to investigate secondary outcomes. The planned second phase will not be undertaken. CANVAS will define the effects of canagliflozin on biomarkers and provide data on cardiovascular safety against established regulatory parameters.
identifier
0ISSN: 0002-8703
1EISSN: 1097-6744
2DOI: 10.1016/j.ahj.2013.05.007
3PMID: 23895803
4CODEN: AHJOA2
languageeng
publisherUnited States: Mosby, Inc
subjectAbridged Index Medicus ; Aged ; Biomarkers - blood ; Blood sugar ; Body mass index ; Canagliflozin ; Cardiology ; Cardiovascular ; Cardiovascular disease ; Cardiovascular Diseases - mortality ; Cardiovascular Medicine ; Clinical trials ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; Drug therapy ; Electrocardiography ; Female ; GLUCOSE ; Glucose metabolism ; Glucosides - adverse effects ; Glucosides - therapeutic use ; Health aspects ; Heart failure ; Hemoglobin ; Humans ; Hypertension ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Male ; Middle Aged ; Plasma ; Regulatory approval ; Research Design ; Sodium-Glucose Transporter 2 - antagonists & inhibitors ; Statins ; Thiophenes - adverse effects ; Thiophenes - therapeutic use ; Triglycerides ; TUBULAR REABSORPTION ; Type 2 diabetes
ispartofAmerican Heart Journal, 2013, Vol.166 (2), p.217-223.e11
rights
0Mosby, Inc.
12013 Mosby, Inc.
2info:eu-repo/semantics/restrictedAccess
3Copyright © 2013 Mosby, Inc. All rights reserved.
4COPYRIGHT 2013 Elsevier B.V.
5Copyright Elsevier Limited Aug 2013
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1705t-c0edb8c5014e19b970ce57a2fa9535af7caaf66a175172a1ed8d7d7c6d6927113
citesFETCH-LOGICAL-1705t-c0edb8c5014e19b970ce57a2fa9535af7caaf66a175172a1ed8d7d7c6d6927113
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23895803$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Neal, Bruce, PhD
1Perkovic, Vlado, PhD
2de Zeeuw, Dick, PhD
3Mahaffey, Kenneth W., MD
4Fulcher, Greg, MD
5Stein, Peter, MD
6Desai, Mehul, MD
7Shaw, Wayne, DSL
8Jiang, Joel, PhD
9Vercruysse, Frank, MD
10Meininger, Gary, MD
11Matthews, David, DPhil
title
0Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
1American Heart Journal
addtitleAm Heart J
descriptionSodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies. Effects on macrovascular complications of diabetes remain to be determined. CANVAS is a double-blind, placebo-controlled trial designed to evaluate the effects of canagliflozin on the risk of cardiovascular disease and to assess safety and tolerability in patients with inadequately controlled T2DM and increased cardiovascular risk. The first of 2 planned phases randomized 4,330 individuals to placebo, canagliflozin 100 or 300 mg (1:1:1) with planned follow-up of about 2 years to substantiate potential cardiovascular protection by assessing key biomarkers and to achieve initial safety objectives. By the end of mid-September 2012, a total of 7174 patient-years of follow-up were accrued. Mean baseline age was 62 years, duration of diabetes 13 years; hemoglobin A1c 8.2%, fasting plasma glucose 9.3 mmol/L, and body mass index 32 kg/m2 . Of the participants, 34% are female and 57% had a history of atherosclerotic vascular disease. Participants will be followed up to achieve primary safety and tolerability objectives and to investigate secondary outcomes. The planned second phase will not be undertaken. CANVAS will define the effects of canagliflozin on biomarkers and provide data on cardiovascular safety against established regulatory parameters.
subject
0Abridged Index Medicus
1Aged
2Biomarkers - blood
3Blood sugar
4Body mass index
5Canagliflozin
6Cardiology
7Cardiovascular
8Cardiovascular disease
9Cardiovascular Diseases - mortality
10Cardiovascular Medicine
11Clinical trials
12Diabetes
13Diabetes Mellitus, Type 2 - drug therapy
14Double-Blind Method
15Drug therapy
16Electrocardiography
17Female
18GLUCOSE
19Glucose metabolism
20Glucosides - adverse effects
21Glucosides - therapeutic use
22Health aspects
23Heart failure
24Hemoglobin
25Humans
26Hypertension
27Hypoglycemic Agents - adverse effects
28Hypoglycemic Agents - therapeutic use
29Male
30Middle Aged
31Plasma
32Regulatory approval
33Research Design
34Sodium-Glucose Transporter 2 - antagonists & inhibitors
35Statins
36Thiophenes - adverse effects
37Thiophenes - therapeutic use
38Triglycerides
39TUBULAR REABSORPTION
40Type 2 diabetes
issn
00002-8703
11097-6744
fulltexttrue
rsrctypearticle
creationdate2013
recordtypearticle
recordideNp9U9tu1DAQjRCIlsIH8IIi8VKk7jLOzYmQkFYrblJVJBZ44cFy7MnWi9de7KSofeIj4Af5Eibd0ooVqvKQjHXOmXHOmSR5zGDKgFXPV1N5uppmwPIplFMAfifZZ9DwScWL4m6yDwDZpOaQ7yUPYlxRWWV1dT_Zy_K6KWvI95NfH2RvvJMWj1KN0SzdUSqdTlsZ0RqHqTqVQaoeg4m9UTH1XdqfYjqXTi6t6ay_MI6qoI0_k1ENVoZ0FiPGuEbXp4t-0Ofp4Xx28nm2ePb7x89ZGkjfr80F6nRjpcLWT5R3ffDW0lEfjLQPk3udtBEfXb0Pkk-vX32cv50cv3_zbj47njAOZT9RgLqtVQmsQNa0DQeFJZdZJ5syL2XHlZRdVUnGS8YzyVDXmmuuKl01GWcsP0hOtrp-g06agGITzFqGc-GlEdphLzTqYSO-dwKAiaoGaJAaUf9clqxoMmioW5HndV0XGQkebgU3wX8bMPZibaJCa6VDP0TBClZBUdI8BH26A135IZAThCrLImuqvKhvUEuySBjX-Z7sGEXFbGwKRc4aQk3_g6JH49rQz8XO0Pk_BLYlqOBjDNhdX5yBGLMlVoKyJcZsCSjp8pw4T64GHto16mvG3zARgO-IKtNfxoumMfZW6S9bppNBmXgtHYblpRObgawZC2fpu7VGXcpGoVRZaca1yNtWiSLLGtEidKKCusCOccRuNOXFVh0pSmcGg4jKoFOoyXFFFntz62wvd9iKFoMmsF_xHOONaSJmAsRiXLpx51gOQA7y_A-7lyWc
startdate2013
enddate2013
creator
0Neal, Bruce, PhD
1Perkovic, Vlado, PhD
2de Zeeuw, Dick, PhD
3Mahaffey, Kenneth W., MD
4Fulcher, Greg, MD
5Stein, Peter, MD
6Desai, Mehul, MD
7Shaw, Wayne, DSL
8Jiang, Joel, PhD
9Vercruysse, Frank, MD
10Meininger, Gary, MD
11Matthews, David, DPhil
general
0Mosby, Inc
1Elsevier B.V
2Elsevier Limited
3Elsevier BV
scope
06I.
1AAFTH
25DI
35DJ
4QVL
5CGR
6CUY
7CVF
8ECM
9EIF
10NPM
11AAYXX
12CITATION
13BSHEE
143V.
157QO
167RV
177TS
187X7
197XB
2088C
2188E
228AO
238C1
248FD
258FI
268FJ
278FK
288G5
29ABUWG
30AN0
31AZQEC
32BENPR
33DWQXO
34FR3
35FYUFA
36GHDGH
37GNUQQ
38GUQSH
39K9.
40KB0
41M0S
42M0T
43M1P
44M2O
45MBDVC
46NAPCQ
47P64
48PADUT
49PQEST
50PQQKQ
51PQUKI
52PRINS
53Q9U
547X8
55BOBZL
56CLFQK
sort
creationdate2013
titleRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
authorNeal, Bruce, PhD ; Perkovic, Vlado, PhD ; de Zeeuw, Dick, PhD ; Mahaffey, Kenneth W., MD ; Fulcher, Greg, MD ; Stein, Peter, MD ; Desai, Mehul, MD ; Shaw, Wayne, DSL ; Jiang, Joel, PhD ; Vercruysse, Frank, MD ; Meininger, Gary, MD ; Matthews, David, DPhil
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1705t-c0edb8c5014e19b970ce57a2fa9535af7caaf66a175172a1ed8d7d7c6d6927113
rsrctypearticles
prefilterarticles
languageeng
creationdate2013
topic
0Abridged Index Medicus
1Aged
2Biomarkers - blood
3Blood sugar
4Body mass index
5Canagliflozin
6Cardiology
7Cardiovascular
8Cardiovascular disease
9Cardiovascular Diseases - mortality
10Cardiovascular Medicine
11Clinical trials
12Diabetes
13Diabetes Mellitus, Type 2 - drug therapy
14Double-Blind Method
15Drug therapy
16Electrocardiography
17Female
18GLUCOSE
19Glucose metabolism
20Glucosides - adverse effects
21Glucosides - therapeutic use
22Health aspects
23Heart failure
24Hemoglobin
25Humans
26Hypertension
27Hypoglycemic Agents - adverse effects
28Hypoglycemic Agents - therapeutic use
29Male
30Middle Aged
31Plasma
32Regulatory approval
33Research Design
34Sodium-Glucose Transporter 2 - antagonists & inhibitors
35Statins
36Thiophenes - adverse effects
37Thiophenes - therapeutic use
38Triglycerides
39TUBULAR REABSORPTION
40Type 2 diabetes
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Neal, Bruce, PhD
1Perkovic, Vlado, PhD
2de Zeeuw, Dick, PhD
3Mahaffey, Kenneth W., MD
4Fulcher, Greg, MD
5Stein, Peter, MD
6Desai, Mehul, MD
7Shaw, Wayne, DSL
8Jiang, Joel, PhD
9Vercruysse, Frank, MD
10Meininger, Gary, MD
11Matthews, David, DPhil
collection
0ScienceDirect Open Access Titles
1Elsevier:ScienceDirect:Open Access
2NARCIS
3NARCIS: Datasets
4NARCIS:Publications
5Medline
6MEDLINE
7MEDLINE (Ovid)
8MEDLINE
9MEDLINE
10PubMed
11CrossRef
12Academic OneFile (A&I only)
13ProQuest Central (Corporate)
14Biotechnology Research Abstracts
15Nursing & Allied Health Database
16Physical Education Index
17Health & Medical Collection
18ProQuest Central (purchase pre-March 2016)
19Healthcare Administration Database (Alumni)
20Medical Database (Alumni Edition)
21ProQuest Pharma Collection
22Public Health Database
23Technology Research Database
24Hospital Premium Collection
25Hospital Premium Collection (Alumni Edition)
26ProQuest Central (Alumni) (purchase pre-March 2016)
27Research Library (Alumni Edition)
28ProQuest Central (Alumni Edition)
29British Nursing Database
30ProQuest Central Essentials
31ProQuest Central
32ProQuest Central Korea
33Engineering Research Database
34Health Research Premium Collection
35Health Research Premium Collection (Alumni)
36ProQuest Central Student
37Research Library Prep
38ProQuest Health & Medical Complete (Alumni)
39Nursing & Allied Health Database (Alumni Edition)
40Health & Medical Collection (Alumni Edition)
41Healthcare Administration Database
42Medical Database
43Research Library
44Research Library (Corporate)
45Nursing & Allied Health Premium
46Biotechnology and BioEngineering Abstracts
47Research Library China
48ProQuest One Academic Eastern Edition
49ProQuest One Academic
50ProQuest One Academic UKI Edition
51ProQuest Central China
52ProQuest Central Basic
53MEDLINE - Academic
54OpenAIRE (Open Access)
55OpenAIRE
jtitleAmerican Heart Journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Neal, Bruce, PhD
1Perkovic, Vlado, PhD
2de Zeeuw, Dick, PhD
3Mahaffey, Kenneth W., MD
4Fulcher, Greg, MD
5Stein, Peter, MD
6Desai, Mehul, MD
7Shaw, Wayne, DSL
8Jiang, Joel, PhD
9Vercruysse, Frank, MD
10Meininger, Gary, MD
11Matthews, David, DPhil
formatjournal
genrearticle
ristypeJOUR
atitleRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
jtitleAmerican Heart Journal
addtitleAm Heart J
date2013
risdate2013
volume166
issue2
spage217
epage223.e11
pages217-223.e11
issn0002-8703
eissn1097-6744
codenAHJOA2
abstractSodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies. Effects on macrovascular complications of diabetes remain to be determined. CANVAS is a double-blind, placebo-controlled trial designed to evaluate the effects of canagliflozin on the risk of cardiovascular disease and to assess safety and tolerability in patients with inadequately controlled T2DM and increased cardiovascular risk. The first of 2 planned phases randomized 4,330 individuals to placebo, canagliflozin 100 or 300 mg (1:1:1) with planned follow-up of about 2 years to substantiate potential cardiovascular protection by assessing key biomarkers and to achieve initial safety objectives. By the end of mid-September 2012, a total of 7174 patient-years of follow-up were accrued. Mean baseline age was 62 years, duration of diabetes 13 years; hemoglobin A1c 8.2%, fasting plasma glucose 9.3 mmol/L, and body mass index 32 kg/m2 . Of the participants, 34% are female and 57% had a history of atherosclerotic vascular disease. Participants will be followed up to achieve primary safety and tolerability objectives and to investigate secondary outcomes. The planned second phase will not be undertaken. CANVAS will define the effects of canagliflozin on biomarkers and provide data on cardiovascular safety against established regulatory parameters.
copUnited States
pubMosby, Inc
pmid23895803
doi10.1016/j.ahj.2013.05.007
oafree_for_read